Moody Aldrich Partners’s Novavax NVAX Stock Holding History

Moody Aldrich Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,180	Closed	-$2.57M	–	187
2021 Q1	$2.57M	Sell	14,180 -7,865	-36%	-$1.57M	0.37%	86
2020 Q4	$2.46M	Sell	22,045 -16	-0.1%	-$1.7K	0.4%	87
2020 Q3	$2.39M	Sell	22,061 -2,596	-11%	-$316K	0.5%	84
2020 Q2	$2.06M	Buy	+24,657	New	+$943K	0.44%	85

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Moody Aldrich Partners's NVAX Position: Q2 2021 in Review

Moody Aldrich Partners sold out of Novavax (NVAX) in Q2 2021, closing a stake of 14,180 shares — an estimated $2.57M sold.

Moody Aldrich Partners first reported a position in NVAX in Q2 2020 and held it in 4 quarters. The position peaked at $2.57M in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Moody Aldrich Partners reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Moody Aldrich Partners sold 14,180 Novavax shares in Q2 2021, an estimated $2.57M.
Moody Aldrich Partners first reported a position in Novavax in Q2 2020 and held it in 4 quarters.
Moody Aldrich Partners's Novavax position peaked at $2.57M in Q1 2021.
407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Moody Aldrich Partners's 13F filing for Q2 2021, filed 4 Aug 2021.